Principia Biopharma, Inc.
(NASDAQ : PRNB)

( )
PRNB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.41%145.110.7%$914.37m
PFEPfizer Inc. 0.27%37.590.9%$786.72m
BMYBristol-Myers Squibb Co. -0.02%60.641.0%$644.35m
MRKMerck & Co., Inc. 0.33%78.550.7%$631.95m
ABBVAbbVie, Inc. 0.14%84.371.9%$591.88m
LLYEli Lilly & Co. -0.38%143.001.1%$498.72m
AZNAstraZeneca Plc -0.46%51.951.2%$200.20m
NVSNovartis AG -0.63%85.150.2%$144.71m
GSKGlaxoSmithKline Plc -1.17%35.620.2%$134.57m
NVONovo Nordisk A/S 0.07%71.250.1%$70.95m
RGENRepligen Corp. 0.00%172.497.1%$63.41m
RPRXRoyalty Pharma Plc 0.20%40.170.2%$59.33m
SNYSanofi -0.46%49.650.2%$48.54m
PRAXPraxis Precision Medicines, Inc. -0.90%27.500.0%$46.97m
AMAGAMAG Pharmaceuticals, Inc. 0.00%13.6422.1%$44.83m

Company Profile

Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.